✦ LIBER ✦

Erratum: Quintás-cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109(2):248–55.

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 22 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22733

No coin nor oath required. For personal study only.

✦ Synopsis

In the article cited above, the dose of HHT should be 2.5 mg/m 2 , not 2 mg/m 2 .

HHT was administered at a rate of 1.25 mg/m 2 s.c. twice daily for 13 days every 28 days until remission, not 14 days.

Results and conclusions of this article remain unchanged.

📜 SIMILAR VOLUMES

Phase I/II study of subcutaneous homohar

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

✍ Alfonso Quintás-Cardama; Hagop Kantarjian; Guillermo Garcia-Manero; Susan O'Brie 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract ## BACKGROUND. Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon. ## METHODS. A Phase I study was com